{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:30:45Z","timestamp":1793302245654,"version":"4.5.0"},"reference-count":54,"publisher":"Korean Society of Pediatric Endocrinology","issue":"2","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-apem.org"],"crossmark-restriction":true},"short-container-title":["Ann Pediatr Endocrinol Metab"],"published-print":{"date-parts":[[2023,6,30]]},"abstract":"<jats:p>Osteogenesis imperfecta (OI) is an inherited skeletal disorder that leads to bone fragility and multiple fractures. Given advances in the genetic understanding of existing phenotypes and newly discovered mutations, therapeutic management of OI has become challenging. Denosumab, a monoclonal antibody that inhibits the interaction between the receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor RANK, has been approved to treat postmenopausal osteoporosis and emerged as an important therapy for malignancies and other skeletal disorders, including pediatric skeletal conditions such as OI. This review summarizes information about denosumab therapy in OI by exploring its mechanisms of action, main indications, and safety and efficacy. Several case reports and small series have been published about the short-term use of denosumab in children with OI. Denosumab was considered a strong drug candidate for OI patients with bone fragility and a high risk of fracture, particularly for patients with the bisphosphonate (BP)-unresponsive OI-VI subtype. The evidence for denosumab's effects in children with OI indicates that it effectively improves bone mineral density but not fracture rates. A decrease in bone resorption markers was observed after each treatment. Safety was assessed by tracking the effects on calcium homeostasis and reporting side effects. No severe adverse effects were reported. Hypercalciuria and moderate hypercalcemia were reported, suggesting that BPs be used to prevent the bone rebound effect. In other words, denosumab can be used as a targeted intervention in children with OI. The posology and administration protocol require more investigation to achieve secure efficiency.<\/jats:p>","DOI":"10.6065\/apem.2346058.029","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:01:47Z","timestamp":1687917707000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.6065\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches"],"prefix":"10.6065","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-6516","authenticated-orcid":true,"given":"Fatma","family":"Majdoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-0936","authenticated-orcid":true,"given":"Hanene Lassoued","family":"Ferjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-5856","authenticated-orcid":true,"given":"Dorra Ben","family":"Nessib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-7573","authenticated-orcid":true,"given":"Dhia","family":"Kaffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-3286","authenticated-orcid":true,"given":"Kaouther","family":"Maatallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-4831","authenticated-orcid":true,"given":"Wafa","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4096","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.06.001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-021-02302-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18699\/vj20.614"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61366"},{"key":"ref5","first-page":"R95","volume-title":"Osteogenesis imperfecta: an update on clinical features and therapies","author":"Marom","year":"2020"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/mop.0000000000000813"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00924"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd005088.pub3"},{"key":"ref9","first-page":"1289","volume-title":"Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?","author":"Yoon","year":"2011"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.533651"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-017-0380-1"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.1.1"},{"key":"ref13","first-page":"86","volume-title":"Skeletal biology over the life span: a view from the surfaces","author":"Gosman","year":"2011"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/421746"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020625"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s8756-3282(00)00269-6"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.02.023"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199810013391402"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000331128"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.10.010"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.242.115"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa023110"},{"key":"ref23","first-page":"385","volume-title":"Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals","author":"Thompson","year":"2012"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900600"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.10.037"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-015-0369-2"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81569-x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3540"},{"key":"ref29","first-page":"309","volume-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","author":"Simonet","year":"1997"},{"key":"ref30","first-page":"490","volume-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","author":"Hofbauer","year":"2004"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2480"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01936-y"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0525-7"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30138-9"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1143"},{"key":"ref36","first-page":"1462","volume-title":"Denosumab treatment for fibrous dysplasia","author":"Boyce","year":"2012"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.06.456"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70277-8"},{"key":"ref39","first-page":"1417","volume-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","author":"Lange","year":"2013"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-022-04455-2"},{"key":"ref41","first-page":"145","volume-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","author":"Hoyer-Kuhn","year":"2014"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3072"},{"key":"ref43","first-page":"24","volume-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","author":"Hoyer-Kuhn","year":"2016"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1197-z"},{"key":"ref45","first-page":"76","volume-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","author":"Trejo","year":"2018"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-016-0110-1"},{"key":"ref47","first-page":"183","volume-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","author":"Semler","year":"2012"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.1.30"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)16051-0"},{"key":"ref50","first-page":"e138","volume-title":"Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition","author":"Zheng","year":"2014"},{"key":"ref51","first-page":"793","volume-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","author":"Sutjandra","year":"2011"},{"key":"ref52","first-page":"534","volume-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","author":"Li","year":"2018"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3081"},{"key":"ref54","first-page":"33","volume-title":"Brief assessment of motor function: reliability and concurrent validity of the Gross Motor Scale","author":"Cintas","year":"2003"}],"container-title":["Annals of Pediatric Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-apem.org\/upload\/pdf\/apem-2346058-029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-apem.org\/journal\/view.php?doi=10.6065\/apem.2346058.029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-apem.org\/upload\/pdf\/apem-2346058-029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:02:56Z","timestamp":1687917776000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-apem.org\/journal\/view.php?doi=10.6065\/apem.2346058.029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.6065\/apem.2346058.029","relation":{},"ISSN":["2287-1012","2287-1292"],"issn-type":[{"value":"2287-1012","type":"print"},{"value":"2287-1292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"2023-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}